Mitsubishi Tanabe and Synageva expand orphan disease collaboration
This article was originally published in Scrip
Executive Summary
Following their initial agreement last year, Mitsubishi Tanabe Pharma (MTP) and Synageva BioPharma have expanded their orphan drug research collaboration to include a second protein therapeutic for an undisclosed disorder.